{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:41:37Z","timestamp":1774716097692,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,10,24]],"date-time":"2007-10-24T00:00:00Z","timestamp":1193184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate the value of a registry, set in \u2018real\u2010life practice\u2019, as a contribution to evidence\u2010based medicine and to estimate the impact of information collected in such a registry, on the up to date knowledge in growth hormone (GH)\u2010related disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Analysis of data collected prospectively for a pharmacoepidemiological registry\u2014KIMS (Pfizer International Metabolic Database)\u2014in assessing long\u2010term clinical and safety outcomes of GH treatment (Genotropin\u00ae) in patients with GH deficiency. The study was based on 11\u2009374 treated (40\u2009000 patient\u2010years of observation) and 263 untreated adult GH deficient patients from 30 countries, in whom background characteristics, clinical values such as lipids and body composition, quality of life (QoL) and GH dosage as well as safety profile were evaluated. Citation analysis for the published papers was also performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study depicts the clinical picture of adult patients with GH deficiency managed in current clinical settings. It confirms the features previously detected such as increased cardiovascular risk, mostly dyslipidemia and abnormal body composition as well as impaired QoL. There was considerable heterogeneity of conditions resulting in GH deficiency. The large database also enabled study of rare causes of the condition. The 31 out of 36 KIMS papers were cited 544 times, in 125 different journals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These findings and the further insight into the response to GH replacement therapy show that the registry methodology is valuable for filling the gaps of information in evidence\u2010based medicine that cannot be addressed by clinical trials. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1510","type":"journal-article","created":{"date-parts":[[2007,10,24]],"date-time":"2007-10-24T07:42:43Z","timestamp":1193211763000},"page":"90-102","source":"Crossref","is-referenced-by-count":51,"title":["Registries as a tool in evidence\u2010based medicine: example of KIMS (Pfizer International Metabolic Database)"],"prefix":"10.1002","volume":"17","author":[{"given":"Lia P.","family":"Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ko\u0142towska\u2010H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders F.","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dag","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Westberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10,24]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"International Society for Pharmacoepidemiology (ISPE).Statement on Regulatory Systems to Improve Pharmaceutical Safety.http:\/\/www.pharmacoepi.org\/resources\/regstatement0205.pdf"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000053134"},{"key":"e_1_2_1_4_2","first-page":"487","article-title":"The potential role of community\u2010based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example","volume":"10","author":"Franciosa JA","year":"2004","journal-title":"Am J Manag Care"},{"key":"e_1_2_1_5_2","first-page":"475","article-title":"The first fifty years of the Connecticut tumour registry: reminiscences and prospects","volume":"59","author":"Haenszel W","year":"1986","journal-title":"Yale J Biol Med"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04021-0"},{"key":"e_1_2_1_7_2","first-page":"450","volume-title":"Modern Epidemiology","author":"Buehler JW"},{"key":"e_1_2_1_8_2","unstructured":"MonsonJ MusseyS.Topical Briefings. Adult growth hormone (GH) replacement (the use of Somatotrophin [GH] in the management of adult Somatotrophin deficiency). Bristol The Society for Endocrinology 2004."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080905"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91812-O"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01559.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262160-00006"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1054\/ghir.2001.0263"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/1740028032000131396"},{"key":"e_1_2_1_15_2","first-page":"346","volume-title":"Growth hormone deficiency in adults. 10 years of KIMS","author":"Abs R","year":"2004"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008987922774"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02176"},{"key":"e_1_2_1_19_2","unstructured":"International Monitoring of Adverse Reactions to Drugs. WHO Adverse Reaction Terminology 31 December2003. The Uppsala Monitoring Center Uppsala Sweden."},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00695.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2005.06.018"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0185"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01877"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02209"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02179"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.11.4291"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.148S009"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01881"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1460067"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01104.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1207"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01884.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021741"},{"key":"e_1_2_1_34_2","unstructured":"National Institute for Clinical Excellence (NICE).Technology Appraisal 64: Human Growth Hormone (Somatotropin) in Adults with Growth Hormone Deficiency. NICE 2003."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1510","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T21:09:41Z","timestamp":1699996181000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1002\/pds.1510"],"URL":"https:\/\/doi.org\/10.1002\/pds.1510","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,24]]}}}